Nautilus Biotechnology (NAUT) Cash from Investing Activities (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Cash from Investing Activities data on file, last reported at $14.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 27.05% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2026 stood at $29.9 million (down 52.77% YoY), and the FY2025 full-year result was $35.2 million, down 46.83% from the prior year.
• Cash from Investing Activities rose to $14.2 million in Q1 2026, from $787000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $37.1 million in Q4 2024 to a low of -$64.1 million in Q4 2022.
• A 5-year average of $2.7 million and a median of $13.1 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 1156.32% in 2022 and jumped 733.88% in 2024, its largest moves.
• Tracing NAUT's Cash from Investing Activities over 5 years: stood at -$64.1 million in 2022, then surged by 35.9% to -$41.1 million in 2023, then surged by 190.37% to $37.1 million in 2024, then sank by 97.88% to $787000.0 in 2025, then jumped by 1708.51% to $14.2 million in 2026.
• Business Quant data shows NAUT's Cash from Investing Activities at $14.2 million in Q1 2026, $787000.0 in Q4 2025, and $452000.0 in Q3 2025.